Product Information
LEVOCETIRIZINE 5 MG TABLET is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.0511 per EA under NDC 31722055190. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 29, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722055190
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVOCETIRIZINE DIHYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA091264FDA Approved
6/29/2012
TE Code
AB
On Market Since
6/29/2012
Pharmacological Classes
Price Statistics
The NADAC for LEVOCETIRIZINE 5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 83.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0511 per EA |
|---|---|
| All-time high | $0.3735 (Apr 16, 2014) |
| All-time low | $0.0511 (Sep 23, 2026) |
| 52-week high | $0.0568 |
| 52-week low | $0.0511 |
| Median price | $0.0857 |
| Average price | $0.1200 |
| Largest weekly change | +51.3% (Apr 18, 2018) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levocetirizine Dihydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVOCETIRIZINE 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LEVOCETIRIZINE 5 MG TABLET, manufactured by Camber Pharmaceuticals Inc., is $0.0511 per EA (NDC 31722055190), effective Sep 30, 2026.
How has the price of LEVOCETIRIZINE 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for LEVOCETIRIZINE 5 MG TABLET has declined 83.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LEVOCETIRIZINE 5 MG TABLET?
Since Nov 28, 2013, the NADAC for LEVOCETIRIZINE 5 MG TABLET has ranged from a low of $0.0511 (Sep 23, 2026) to a high of $0.3735 (Apr 16, 2014), with a median of $0.0857 per EA.
Are there cheaper alternatives to LEVOCETIRIZINE 5 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LEVOCETIRIZINE 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LEVOCETIRIZINE 5 MG TABLET?
LEVOCETIRIZINE 5 MG TABLET (NDC 31722055190) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.